IL164984A0 - Use of epa and dha in secondary prevention - Google Patents

Use of epa and dha in secondary prevention

Info

Publication number
IL164984A0
IL164984A0 IL16498404A IL16498404A IL164984A0 IL 164984 A0 IL164984 A0 IL 164984A0 IL 16498404 A IL16498404 A IL 16498404A IL 16498404 A IL16498404 A IL 16498404A IL 164984 A0 IL164984 A0 IL 164984A0
Authority
IL
Israel
Prior art keywords
dha
epa
secondary prevention
prevention
Prior art date
Application number
IL16498404A
Other languages
English (en)
Original Assignee
Pronova Biocare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29404296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL164984(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0210212.7A external-priority patent/GB0210212D0/en
Application filed by Pronova Biocare As filed Critical Pronova Biocare As
Publication of IL164984A0 publication Critical patent/IL164984A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16498404A 2002-05-03 2004-11-02 Use of epa and dha in secondary prevention IL164984A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210212.7A GB0210212D0 (en) 2002-05-03 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0307625A GB2388026B (en) 2002-05-03 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes
PCT/GB2003/001945 WO2003092673A1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention

Publications (1)

Publication Number Publication Date
IL164984A0 true IL164984A0 (en) 2005-12-18

Family

ID=29404296

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16498404A IL164984A0 (en) 2002-05-03 2004-11-02 Use of epa and dha in secondary prevention

Country Status (9)

Country Link
EP (1) EP1501493B1 (de)
CN (1) CN1665496B (de)
AU (1) AU2003229993B2 (de)
BR (1) BR0309740A (de)
CA (1) CA2485116C (de)
IL (1) IL164984A0 (de)
NO (1) NO334959B1 (de)
NZ (1) NZ548508A (de)
WO (1) WO2003092673A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
US7498359B2 (en) 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
CN101049297B (zh) * 2006-04-06 2010-11-24 北京百慧生化制药有限责任公司 一种高dha型-乙酯和epa-乙酯的脂肪酸乙酯及其制造方法和制剂
US20110166228A1 (en) 2006-11-01 2011-07-07 Anne Kristin Holmeide Composition
WO2008053331A1 (en) 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).
CN101646426A (zh) * 2006-11-03 2010-02-10 普罗诺瓦生物医药挪威公司 ω-3脂质化合物
KR101430214B1 (ko) 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
KR20110098909A (ko) * 2008-11-14 2011-09-02 보미 피. 팜로즈 동맥경화증의 치료를 위한, 순환하는 산화된 저밀도 지방단백질-베타-2-당단백질 1 복합체를 낮추는 방법
EP3563842A1 (de) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit epa und einem kardiovaskulären mittel sowie verfahren zur verwendung davon
RU2538691C2 (ru) 2009-04-29 2015-01-10 Амарин Фарма, Инк. Стабильные фармацевтические композиции и способы их применения
LT3318255T (lt) 2009-06-15 2021-05-25 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011048493A1 (en) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
US20110178105A1 (en) * 2010-01-15 2011-07-21 E.I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (de) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Verfahren zur behandlung von hypertriglyceridämie
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (de) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
TW201334808A (zh) * 2012-02-29 2013-09-01 Braun Melsungen Ag 含有荷爾蒙之包含磷蝦磷脂質的乳劑
EP4342546A3 (de) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Verfahren zur verringerung des risikos von herz-kreislauf-ereignissen bei einem patienten in einer statintherapie
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140249225A1 (en) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) * 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN113884586A (zh) * 2021-06-17 2022-01-04 上海市肺科医院 一种特发性肺动脉高压的预后标记物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210122B (en) * 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Also Published As

Publication number Publication date
AU2003229993B2 (en) 2008-07-24
EP1501493B1 (de) 2009-10-07
WO2003092673A1 (en) 2003-11-13
CN1665496B (zh) 2010-05-05
AU2003229993A1 (en) 2003-11-17
CA2485116A1 (en) 2003-11-13
EP1501493A1 (de) 2005-02-02
NO20045275L (no) 2005-01-31
CN1665496A (zh) 2005-09-07
NZ548508A (en) 2008-04-30
NO334959B1 (no) 2014-08-04
CA2485116C (en) 2013-02-05
BR0309740A (pt) 2005-02-22

Similar Documents

Publication Publication Date Title
IL164984A0 (en) Use of epa and dha in secondary prevention
HK1070558A1 (en) Co-beadlet of dha and rosemary and methods of use
PL1699449T3 (pl) Zastosowanie kompozycji kwasów tłuszczowych obejmującej co najmniej jeden z EPA i DHA lub jakąkolwiek ich kombinację
SI2075000T1 (sl) Kombinacija azelastina in ciklezonida
GB0515801D0 (en) Time in databases and applications of databases
AU2001268535A1 (en) Devices and methods for repair of valves in the human body
PL372395A1 (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
PL374598A1 (en) Caspase inhibitors and uses thereof
EP1543034A4 (de) Behandlung und prophylaxe mit 4-1bb-bindenden mitteln
EP1551384A4 (de) R-nsaid-ester und ihre verwendung
EP1586332A4 (de) Kombinierte verwendung voncarnosinas-inhibitor mit l-carnosinen und zusammensetzung
SI1536782T1 (sl) Sinergistična kombinacija alfa-2-delta liganda in PDEV-inhibitorja za uporabo pri zdravljenju bolečine
AU2002359512A8 (en) Belts and methods of use thereof
GB0219996D0 (en) Improvemnts in and to dispensing devices
EP1476150A4 (de) Carboxyfullerene und verwendungsverfahren dafür
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2002230036A8 (en) Glucosamine-polyacrylate inter-polymer complex and applications thereof
PL375631A1 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
GB0101699D0 (en) Improvements in and relating to taps
PL363544A1 (en) Piperazino-derivatives and their use as pde4 inhibitor
EP1616873A4 (de) Lipidregulierendes mittel und dessen verwendung
AU2003274963A8 (en) Mda-7 and free radicals in the treatment of cancer
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
AU2003228355A8 (en) Adipocytes and uses thereof